![Peter Svalander](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Svalander
Corporate Officer/Principal at University of Gothenburg
Peter Svalander active positions
Companies | Position | Start | End |
---|---|---|---|
University of Gothenburg | Corporate Officer/Principal | 2010-06-01 | - |
Career history of Peter Svalander
Former positions of Peter Svalander
Companies | Position | Start | End |
---|---|---|---|
Swedish Biotechnology AB | President | - | - |
Avaris AB
![]() Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Director/Board Member | - | - |
Statistics
International
Sweden | 4 |
Operational
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
President | 1 |
Sectoral
Commercial Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Avaris AB
![]() Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
Swedish Biotechnology AB |
- Stock Market
- Insiders
- Peter Svalander
- Experience